|
Chemotherapy Related Anemia in Patients with Non-Myeloid Malignancies Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Chemotherapy Related Anemia in Patients with Non-Myeloid Malignancies conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Chemotherapy Related Anemia in Patients with Non-Myeloid Malignancies Clinical research trials and Chemotherapy Related Anemia in Patients with Non-Myeloid Malignancies healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Chemotherapy Related Anemia in Patients with Non-Myeloid Malignancies. Chemotherapy Related Anemia in Patients with Non-Myeloid Malignancies Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Chemotherapy Related Anemia in Patients with Non-Myeloid Malignancies clinical trial. Participants typically obtain the most effective healthcare available for their Chemotherapy Related Anemia in Patients with Non-Myeloid Malignancies condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Chemotherapy Related Anemia in Patients with Non-Myeloid Malignancies  Chemotherapy Related Anemia in Patients with Non-Myeloid Malignancies
Chemotherapy Related Anemia in Patients with Non-Myeloid Malignancies
For Condition: Breast Neoplasms,Lung Neoplasms,Multiple Myeloma,Leukemia, Lymphocytic, Chronic,Lymphomas
Status: Completed
Sponsor(s): Amgen ,
Synopsis: Chemotherapy can often cause anemia in patients with cancer. Anemia is a low number of red blood cells. The symptoms of anemia may include fatigue, dizziness, headache, chest pain, and shortness of breath. Erythropoietin is a hormone made by the kidneys that signals the bone marrow to produce more red blood cells. Recombinant human erythropoietin has been produced in the laboratory and has the same effect as the hormone produced by the body. Use of recombinant human erythropoietin allows the body to produce more red blood cells, possibly eliminating or decreasing your symptoms and the need for a red blood cell transfusion. Recombinant human erythropoietin is FDA approved to treat anemia in cancer patients receiving chemotherapy. This clinical study is investigating the effectiveness of darbepoetin alfa for the treatment of anemia in patients with non-myeloid malignancies who are receiving chemotherapy every three weeks. Darbepoetin alfa is a recombinant erythropoietic protein that stimulates the production of red blood cells. This medication has not been approved to treat cancer patients with anemia, however it has been approved by the FDA to treat chronic renal failure patients with anemia.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Patients with non-myeloid malignancies - Patients receiving at least 12 weeks of chemotherapy on a 3-week cycle schedule - Patients with anemia (hgb >/= 9.0 and
Total Enrollment:
Location and Contact Information:
Research Center
Philadelphia, Pennsylvania,
United States
Additional Information:
Study ID Numbers: 20010162;
Study Start Date:
Record last reviewed: January 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00036023
Other Lung Neoplasms Studies:
1. Comparison of Nolvadex 20 mg and placebo combination to Nolvadex 20 mg and ZD1839 (IRESSA™) 250 mg combination in patients with metastatic breast cancer and estrogen receptor (ER) and/or progesterone (PR) positive tumours
2. A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer
3. A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer
4. Evaluation of Bay 59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
5. A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy with G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients
Related Studies:
Other Lung Neoplasms Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
Chemotherapy Related Anemia in Patients with Non-Myeloid Malignancies
|
|
|
|
|
|
|
|
